Evidence map›Paper›PMID 37606435›Full record

ArticleAntibodies (Basel, Switzerland)2023

Cost-Effective Protein Production in CHO Cells Following Polyethylenimine-Mediated Gene Delivery Showcased by the Production and Crystallization of Antibody Fabs.

Klaudia Meskova, Katarina Martonova, Patricia Hrasnova, Kristina Sinska, Michaela Skrabanova, Lubica Fialova, Stefana Njemoga, Ondrej Cehlar, Olga Parmar, Petr Kolenko and 2 more

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Klaudia MeskovaInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.
Katarina MartonovaInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.
Patricia HrasnovaInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.
Kristina SinskaAXON Neuroscience R&D Services SE, 811 02 Bratislava, Slovakia.
Michaela SkrabanovaInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.
Lubica FialovaInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.
Stefana NjemogaInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.
Ondrej CehlarInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.ORCID 0000-0002-1996-6812
Olga ParmarInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.
Petr KolenkoFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, 115 19 Prague, Czech Republic.
Vladimir PevalaInstitute of Molecular Biology, Slovak Academy of Sciences, 845 51 Bratislava, Slovakia.ORCID 0000-0001-5110-8837
Rostislav SkrabanaInstitute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.ORCID 0000-0001-8200-5275
Slovak Academy of Sciences · SKAXON Neuroscience (Slovakia) · SKCzech Technical University in Prague · CZ

Funding

Slovak Research and Development Agency APVV-21-0479, APVV-20-0513VEGA 2/0152/21, 2/0141/23, 2/0125/23
6 · The paper itself

Abstract

Laboratory production of recombinant mammalian proteins, particularly antibodies, requires an expression pipeline assuring sufficient yield and correct folding with appropriate posttranslational modifications. Transient gene expression (TGE) in the suspension-adapted Chinese Hamster Ovary (CHO) cell lines has become the method of choice for this task. The antibodies can be secreted into the media, which facilitates subsequent purification, and can be glycosylated. However, in general, protein production in CHO cells is expensive and may provide variable outcomes, namely in laboratories without previous experience. While achievable yields may be influenced by the nucleotide sequence, there are other aspects of the process which offer space for optimization, like gene delivery method, cultivation process or expression plasmid design. Polyethylenimine (PEI)-mediated gene delivery is frequently employed as a low-cost alternative to liposome-based methods. In this work, we are proposing a TGE platform for universal medium-scale production of antibodies and other proteins in CHO cells, with a novel expression vector allowing fast and flexible cloning of new genes and secretion of translated proteins. The production cost has been further reduced using recyclable labware. Nine days after transfection, we routinely obtain milligrams of antibody Fabs or human lactoferrin in a 25 mL culture volume. Potential of the platform is established based on the production and crystallization of antibody Fabs and their complexes.

Indexed as

CHO cell linegene deliverypolyethylenimineproduction costsprotein crystallographyrecombinant protein production

Identifiers

PMID37606435
PMCPMC10443350
OpenAlexW4385577756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.